PMID- 32006159
OWN - NLM
STAT- MEDLINE
DCOM- 20210623
LR  - 20240402
IS  - 1432-1459 (Electronic)
IS  - 0340-5354 (Print)
IS  - 0340-5354 (Linking)
VI  - 268
IP  - 7
DP  - 2021 Jul
TI  - Efficacy and safety of galcanezumab for preventive treatment of migraine: a 
      systematic review and meta-analysis.
PG  - 2364-2376
LID - 10.1007/s00415-020-09707-5 [doi]
AB  - OBJECTIVE: This meta-analysis aimed to systematically evaluate the effectiveness 
      and safety of galcanezumab in the prophylactic treatment of adult migraine. 
      METHODS: A systematic literature search was performed to identity 
      randomized-controlled trials (RCTs). The primary outcome was the decline in the 
      number of monthly migraine days (MMDs). Secondary outcomes included the reduction 
      of monthly acute migraine‑specific medication days (MSMDs), the number of 
      participants showing a reduction in MMDs from baseline of >/= 50%, >/= 75%, and 100%, 
      the incidence of adverse events (AEs), and the number of participants developing 
      anti-drug antibodies (ADAs) to galcanezumab. We calculated the mean difference 
      (MD), relative risk (RR), and 95% confidence intervals (CIs) for these outcomes. 
      RESULTS: Among the five included trials, galcanezumab given at doses of 120, 150, 
      240, and 300 mg was superior to placebo for both MMDs and secondary outcomes. The 
      degree of AEs in all group was mild. Notably, no significant differences were 
      found in the occurrence of AEs and ADAs between the galcanezumab and placebo 
      groups. CONCLUSION: Galcanezumab is a safe and effective treatment for adult 
      patients with episodic and chronic migraine.
FAU - Zhao, Xiuyuan
AU  - Zhao X
AD  - Tianjin Medical University, Tianjin, China.
FAU - Xu, Xiaolin
AU  - Xu X
AD  - Neurology, Tianjin Huanhu Hospital, Tianjin, China. hhyyxxl@163.com.
FAU - Li, Qingyun
AU  - Li Q
AD  - Neurology, Tianjin Huanhu Hospital, Tianjin, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20200131
PL  - Germany
TA  - J Neurol
JT  - Journal of neurology
JID - 0423161
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 55KHL3P693 (galcanezumab)
SB  - IM
EIN - J Neurol. 2021 Feb 8;:. PMID: 33555421
MH  - Adult
MH  - *Antibodies, Monoclonal, Humanized
MH  - Double-Blind Method
MH  - Humans
MH  - *Migraine Disorders/drug therapy/prevention & control
MH  - Treatment Outcome
PMC - PMC8217057
OTO - NOTNLM
OT  - Galcanezumab
OT  - Meta-analysis
OT  - Migraine
OT  - Prophylaxis
COIS- The authors declare that they have no conflict of interest.
EDAT- 2020/02/02 06:00
MHDA- 2021/06/24 06:00
PMCR- 2020/01/31
CRDT- 2020/02/02 06:00
PHST- 2019/11/14 00:00 [received]
PHST- 2020/01/10 00:00 [accepted]
PHST- 2020/01/08 00:00 [revised]
PHST- 2020/02/02 06:00 [pubmed]
PHST- 2021/06/24 06:00 [medline]
PHST- 2020/02/02 06:00 [entrez]
PHST- 2020/01/31 00:00 [pmc-release]
AID - 10.1007/s00415-020-09707-5 [pii]
AID - 9707 [pii]
AID - 10.1007/s00415-020-09707-5 [doi]
PST - ppublish
SO  - J Neurol. 2021 Jul;268(7):2364-2376. doi: 10.1007/s00415-020-09707-5. Epub 2020 
      Jan 31.